Landscape → Infectious Disease

Bacterial Infections Clinical Trial Landscape

Data updated: May 20, 2026

172 clinical trials tracked since 2008

Bacterial Infections is being studied across 172 clinical trials registered since 2008, with 26 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 8 active Phase 2 trials, and 4 active Phase 1 trials. Top industry sponsors include Pfizer, Qpex Biopharma, Inc., CanSino Biologics Inc..

26 active

172 total (since 2008)

Phase 1 Active

78 total

Phase 2 Active

36 total

Phase 3 Active

35 total

Phase 4 Active

32 total

Top Industry Sponsors

Sorted by active Active Done Failed

Pfizer 2 7 2

Qpex Biopharma, Inc. 1 8 0

CanSino Biologics Inc. 1 2 0

Grifols Therapeutics LLC 1 0 0

Bausch Health Americas, Inc. 1 0 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06592586 ACTIVE NOT RECRUITING

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Minervax ApS n=338

NCT05645107 RECRUITING

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Grifols Therapeutics LLC n=386

NCT07017777 RECRUITING

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

CanSino Biologics Inc. n=600

NCT03969901 COMPLETED

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Merck Sharp & Dohme LLC n=115

NCT03925480 COMPLETED

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

Murdoch Childrens Research Institute n=2,110

+ 30 more Phase 3 trials — see full database below

Bacterial Infections — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Pfizer

Qpex Biopharma, Inc.

CanSino Biologics Inc.

Grifols Therapeutics LLC

Bausch Health Americas, Inc.

Vasomune Therapeutics, Inc.

Joincare Pharmaceutical Group Industry Co., Ltd

Saptalis Pharmaceuticals LLC

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Merck

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

51-200

201-500

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Pfizer 2 7 2

Qpex Biopharma, Inc. 1 8 0

CanSino Biologics Inc. 1 2 0

Grifols Therapeutics LLC 1 0 0

Bausch Health Americas, Inc. 1 0 0

Vasomune Therapeutics, Inc. 1 0 0

Joincare Pharmaceutical Group Industry Co., Ltd 1 0 0

Saptalis Pharmaceuticals LLC 1 0 0

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) 1 0 0

Merck 0 7 0

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 0 5 0

Melinta Therapeutics, Inc. 0 5 0

Evopoint Biosciences Inc. 0 4 0

Tetraphase Pharmaceuticals, Inc 0 4 0

MCM Vaccines B.V. 0 4 0

NCT06592586 ACTIVE NOT RECRUITING

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Minervax ApS n=338

NCT05645107 RECRUITING

Grifols Therapeutics LLC n=386

NCT07503600 NOT YET RECRUITING

The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections

Ain Shams University n=70

NCT07017777 RECRUITING

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

CanSino Biologics Inc. n=600

NCT06444802 NOT YET RECRUITING

Model-informed Precision Dosing for Linezolid

University of Hamburg-Eppendorf n=28

NCT03969901 COMPLETED

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Merck Sharp & Dohme LLC n=115

NCT03925480 COMPLETED

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

Murdoch Childrens Research Institute n=2,110

NCT03896685 COMPLETED

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Médecins Sans Frontières, France n=323

NCT02814916 COMPLETED

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

AbbVie n=199

NCT04841369 COMPLETED

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

CanSino Biologics Inc. n=3,420

NCT03580044 TERMINATED

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Pfizer n=15

NCT04847921 TERMINATED

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

University of Colorado, Denver n=11

NCT05689229 COMPLETED

Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial

Beni-Suef University n=128

NCT01817075 COMPLETED

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

Children's Oncology Group n=177

NCT01371656 COMPLETED

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Children's Oncology Group n=624

NCT01341639 COMPLETED

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

MCM Vaccines B.V. n=1,250

NCT01480258 COMPLETED

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

MCM Vaccines B.V. n=1,315

NCT01553279 COMPLETED

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

MCM Vaccines B.V. n=284

NCT02378480 COMPLETED

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Paratek Pharmaceuticals Inc n=655

NCT01839188 COMPLETED

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

MCM Vaccines B.V. n=385

NCT02753387 COMPLETED

Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer

Rennes University Hospital n=80

NCT02877927 COMPLETED

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Paratek Pharmaceuticals Inc n=735

NCT01337167 COMPLETED

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Merck Sharp & Dohme LLC n=1,473

NCT01340937 COMPLETED

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Merck Sharp & Dohme LLC n=2,808

NCT02452047 COMPLETED

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

Merck Sharp & Dohme LLC n=50

NCT01421511 COMPLETED

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=666

NCT01170221 COMPLETED

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=667

NCT03124199 COMPLETED

Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa n=40

NCT01984684 COMPLETED

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Melinta Therapeutics, Inc. n=850

NCT01811732 COMPLETED

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Melinta Therapeutics, Inc. n=660

NCT01839175 COMPLETED

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Sanofi Pasteur, a Sanofi Company n=350

NCT02066402 COMPLETED

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Bayer n=598

NCT02361866 COMPLETED

To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults

Green Cross Corporation n=376

NCT01402713 COMPLETED

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

Green Cross Corporation n=311

NCT01608815 COMPLETED

Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects

Sanofi Pasteur, a Sanofi Company n=200

NCT06462235 RECRUITING

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Pfizer

NCT07550595 NOT YET RECRUITING

Oritavancin for Treatment of Serious Cardiac Infections

Kirby Institute

NCT05639647 RECRUITING

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Pfizer

NCT05632315 ACTIVE NOT RECRUITING

PMT for MDRO Decolonization

University of Pennsylvania

NCT05123755 RECRUITING

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Vasomune Therapeutics, Inc.

NCT07146217 NOT YET RECRUITING

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Saptalis Pharmaceuticals LLC

NCT06135350 RECRUITING

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

NCT06086626 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Shionogi

NCT04335539 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Shionogi

NCT04215991 COMPLETED

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Shionogi

NCT02269319 COMPLETED

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

MicuRx

NCT02690181 COMPLETED

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

GlaxoSmithKline

NCT04126031 TERMINATED

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

Pfizer

NCT05269121 WITHDRAWN

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

Adaptive Phage Therapeutics, Inc.

NCT03964493 COMPLETED

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

TenNor Therapeutics Limited

NCT03747497 COMPLETED

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

MicuRx

NCT03978091 COMPLETED

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02436876 COMPLETED

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

Microbion Corporation

NCT01119105 COMPLETED

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Nabriva Therapeutics AG

NCT02426918 COMPLETED

Study of Debio 1450 for Bacterial Skin Infections

Debiopharm International SA

NCT01283581 COMPLETED

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

Melinta Therapeutics, Inc.

NCT02052388 COMPLETED

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Cellceutix Corporation

NCT00633152 COMPLETED

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Forest Laboratories

NCT01746654 COMPLETED

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

GangaGen, Inc.

NCT01528969 COMPLETED

Effect of Xylitol on Oral Microbiota in Children

Kuwait University

NCT00430469 WITHDRAWN

Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients

AM-Pharma

NCT01412801 COMPLETED

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings

Novartis Vaccines

NCT01446289 COMPLETED

Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings

Novartis

NCT01252199 COMPLETED

Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

Thallion Pharmaceuticals

NCT01519492 COMPLETED

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

Affinium Pharmaceuticals, Ltd

NCT00511186 TERMINATED

A Study in Sepsis Patients With Renal Failure

AM-Pharma

NCT00723502 COMPLETED

Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients

MerLion Pharmaceuticals GmbH

NCT04263792 RECRUITING

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

University of Pennsylvania

NCT07104162 RECRUITING

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

Qpex Biopharma, Inc.

NCT07207291 RECRUITING

Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

Joincare Pharmaceutical Group Industry Co., Ltd

NCT02687906 ACTIVE NOT RECRUITING

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

NCT05217537 COMPLETED

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Paratek Pharmaceuticals Inc

NCT03424525 COMPLETED

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

University of Pennsylvania

NCT06079775 COMPLETED

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

Qpex Biopharma, Inc.

NCT02134301 COMPLETED

Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

Melinta Therapeutics, LLC

NCT06547554 COMPLETED

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Qpex Biopharma, Inc.

NCT07070375 COMPLETED

Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function

Jiangsu HengRui Medicine Co., Ltd.

NCT06157242 COMPLETED

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

Qpex Biopharma, Inc.

NCT05590728 COMPLETED

Safety of Intravenous Apramycin in Adults

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05584683 COMPLETED

A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection

Kaizen Bioscience Co.

NCT05645757 COMPLETED

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05684705 COMPLETED

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

BioVersys AG

NCT04874948 COMPLETED

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

Michael Hoelscher

NCT02013141 TERMINATED

Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)

Cumberland Pharmaceuticals

NCT05942820 TERMINATED

The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers

Bugworks Research Inc.

NCT03230916 COMPLETED

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Merck Sharp & Dohme LLC

NCT05614895 COMPLETED

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

Hoffmann-La Roche

NCT05684718 COMPLETED

To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100

BioVersys AG

NCT03910673 COMPLETED

Intravenous Fosfomycin Pharmacokinetics Study

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05088421 COMPLETED

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers

Bugworks Research Inc.

NCT02527681 TERMINATED

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Basilea Pharmaceutica

NCT04802863 COMPLETED

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

Evopoint Biosciences Inc.

NCT04801043 COMPLETED

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

Evopoint Biosciences Inc.

NCT04482569 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

Evopoint Biosciences Inc.

NCT04787562 COMPLETED

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Evopoint Biosciences Inc.

NCT04100772 COMPLETED

Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

CanSino Biologics Inc.

NCT05226923 COMPLETED

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Sumitovant Biopharma, Inc.

NCT04808414 COMPLETED

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

Qpex Biopharma, Inc.

NCT04578873 COMPLETED

Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

Qpex Biopharma, Inc.

NCT04380207 COMPLETED

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

Qpex Biopharma, Inc.

NCT03939429 COMPLETED

Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects

Qpex Biopharma, Inc.

NCT05072444 COMPLETED

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Qpex Biopharma, Inc.

NCT02688790 TERMINATED

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

AbbVie

NCT03450187 COMPLETED

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

Tetraphase Pharmaceuticals, Inc

NCT03024034 COMPLETED

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

Tetraphase Pharmaceuticals, Inc

NCT03234738 COMPLETED

A Phase 1 Safety and PK Study of IV TP-271

Tetraphase Pharmaceuticals, Inc

NCT03696550 COMPLETED

A Safety and PK Study of IV Eravacycline

Tetraphase Pharmaceuticals, Inc

NCT01949103 COMPLETED

TD-1607 MAD Study in Healthy Subjects

Theravance Biopharma

NCT02475876 COMPLETED

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

Michael Cohen-Wolkowiez

NCT03361163 COMPLETED

Controlled Human Infection for Vaccination Against Streptococcus Pyogenes

Andrew Steer

NCT02750761 COMPLETED

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Merck Sharp & Dohme LLC

NCT01271998 COMPLETED

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT01019395 COMPLETED

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT02266706 COMPLETED

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03590600 COMPLETED

A Single Ascending Dose Study of BTZ043

Michael Hoelscher

NCT01015014 COMPLETED

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

Pfizer

NCT01156077 COMPLETED

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT03332732 COMPLETED

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Venatorx Pharmaceuticals, Inc.

NCT03182504 COMPLETED

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Hoffmann-La Roche

NCT01689207 COMPLETED

To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)

Pfizer

NCT02955459 COMPLETED

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Venatorx Pharmaceuticals, Inc.

NCT02268279 COMPLETED

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

Melinta Therapeutics, Inc.

NCT01966055 COMPLETED

Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents

Melinta Therapeutics, Inc.

NCT01744730 COMPLETED

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

Phillip Brian Smith

NCT01059890 COMPLETED

Cerebral Antibiotics Distribution After Acute Brain Injury

Poitiers University Hospital

NCT00983255 COMPLETED

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT01946568 COMPLETED

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Durata Therapeutics Inc., an affiliate of Allergan plc

NCT02214433 COMPLETED

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Debiopharm International SA

NCT02134834 COMPLETED

A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

Meiji Seika Pharma Co., Ltd.

NCT02162199 COMPLETED

A Single Dose Study of Debio 1450 in Healthy Subjects

Debiopharm International SA

NCT02146209 COMPLETED

Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.

Verisfield UK Ltd. Greek Branch

NCT01897779 COMPLETED

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

NCT01018641 COMPLETED

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Pfizer

NCT01751269 COMPLETED

Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

NCT01772836 COMPLETED

Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

NCT01381848 COMPLETED

A Study of Doripenem in Infants Less Than 12 Weeks of Age

Janssen Research & Development, LLC

NCT01702649 COMPLETED

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

NCT01058824 COMPLETED

Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule

Pfizer

NCT00795145 COMPLETED

A Study To Assess The Effect Of Linezolid On QTc Interval

Pfizer

NCT00678106 COMPLETED

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Pfizer

NCT06709521 RECRUITING

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07547826 NOT YET RECRUITING

Efficacy and Cost-Effectiveness of Topical Vancomycin Powder in Preventing Pediatric Ventriculoperitoneal Shunt Infections Across Different Etiologies

Assiut University

NCT07285785 RECRUITING

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Bausch Health Americas, Inc.

NCT07478484 RECRUITING

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Jing Zhou

NCT05914467 ACTIVE NOT RECRUITING

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Radboud University Medical Center

NCT05922124 RECRUITING

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Rambam Health Care Campus

NCT03671967 RECRUITING

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Rambam Health Care Campus

NCT07004049 RECRUITING

Optimising TREATment for Severe Gram-Negative Bacterial Infections

National University of Singapore

NCT05783661 RECRUITING

Trial Comparing Conventional Antibiotic Strategies Versus Regimens Guided by Epidemiological Surveillance in Infected Patients With Cirrhosis (SURVIC_STUDY)

Eva Bonfill

NCT07590648 NOT YET RECRUITING

Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia

Hospital Universitari Vall d'Hebron Research Institute

NCT02572791 COMPLETED

Staph Household Intervention for Eradication (SHINE)

Washington University School of Medicine

NCT07122596 COMPLETED

EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS

Pakistan Navy Station Shifa Hospital

NCT05355350 WITHDRAWN

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

Rambam Health Care Campus

NCT04785924 WITHDRAWN

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Wake Forest University Health Sciences

NCT03982030 WITHDRAWN

Dalbavancin Outpatient Pilot

Wake Forest University Health Sciences

NCT05586438 COMPLETED

Pharmacokinetics of Colistin in Critically-ill Patients With AKI Who Receive SLED

Mahidol University

NCT01506986 COMPLETED

Helicobacter Eradication Aspirin Trial

University of Nottingham

NCT03369951 COMPLETED

Minocycline Pharmacokinetics (ACUMIN)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03397914 COMPLETED

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

National Cancer Institute, Egypt

NCT03233438 COMPLETED

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Allergan

NCT01968395 COMPLETED

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

Erasme University Hospital

NCT01732250 COMPLETED

Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem

Mical Paul

NCT02500654 COMPLETED

Regenerative Surgical Treatment of Peri-implantitis

Catrine Isehed

NCT02285075 COMPLETED

Temocillin Pharmacokinetic in Hemodialysis

AZ Sint-Jan AV

NCT02079298 COMPLETED

Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants

Anders Rane, MD, PhD, Senior professor

NCT01623154 COMPLETED

POCone-UBiT-IR300 Pediatric Comparison Study

Otsuka America Pharmaceutical

NCT02092506 COMPLETED

RCT: Triple vs Sequential vs Concomitant Therapy H Pylori

Changi General Hospital

NCT01244698 COMPLETED

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

Stony Brook University

NCT00965848 COMPLETED

A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections

Janssen-Cilag Ltd.,Thailand

NCT00407147 TERMINATED

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

Brahms AG

NCT00575367 COMPLETED

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Merck Sharp & Dohme LLC

NCT00939562 COMPLETED

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

Pfizer

Full Bacterial Infections Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only